MK-912 is a potent new selective alpha 2-adrenergic receptor antagonist that is active orally , to study the effect of short-term, selective alpha 2-blockade on fasting plasma glucose (FPG) and pancreatic islet function in non-insulin-dependent diabetes (NIDDM). References: Qin X, Frech P. Liquid chromatography/mass spectrometry (LC/MS) identification of photooxidative degradates of crystalline and amorphous MK-912. J Pharm Sci. 2001 Jul;90(7):833-44. PubMed PMID: 11458333. 2: Shiue C, Pleus RC, Shiue GG, Rysavy JA, Sunderland JJ, Cornish KG, Young SD, Bylund DB. Synthesis and biological evaluation of [11C]MK-912 as an alpha2-adrenergic receptor radioligand for PET studies. Nucl Med Biol. 1998 Feb;25(2):127-33. PubMed PMID: 9468027. 3: Uhlén S, Xia Y, Chhajlani V, Felder CC, Wikberg JE. [3H]-MK 912 binding delineates two alpha 2-adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d alpha 2-adrenoceptor. Br J Pharmacol. 1992 Aug;106(4):986-95. Erratum in: Br J Pharmacol 1993 Mar;108(3):852. PubMed PMID: 1356570; PubMed Central PMCID: PMC1907663. 4: Ortiz-Alonso FJ, Herman WH, Gertz BJ, Williams VC, Smith MJ, Halter JB. Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus. Metabolism. 1991 Nov;40(11):1160-7. PubMed PMID: 1682787. 5: Warren JB, Dollery CT, Fuller RW, Williams VC, Gertz BJ. Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103-9. PubMed PMID: 2568210. 6: Pettibone DJ, Flagg SD, Totaro JA, Clineschmidt BV, Huff JR, Young SD, Chen R. [3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors. Life Sci. 1989;44(7):459-67. PubMed PMID: 2564617.

纯度：≥98%

CAS：119942-70-0